A cyclin-dependent kinase 4/6 (CDK) inhibitor (CDKi) blocks AP-1 transcription by decreasing Jun stability, thus blocking the production of MMP3 and attenuating cartilage destruction in the collagen-induced arthritis model (119). Here, FOS is linked to arthritic joint disease.